Cohance Lifesciences Ltd vs Sotac Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 07, 2026

Key Highlights

The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 486.25 as of 07 May 12:02 . The P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 yearsThe P/E Ratio of Sotac Pharmaceuticals Ltd changed from 31.3 on March 2024 to 16.4 on March 2025 . This represents a CAGR of -27.61% over 2 years The Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 yearsThe Market Cap of Sotac Pharmaceuticals Ltd changed from ₹ 133.71 crore on March 2024 to ₹ 131.22 crore on March 2025 . This represents a CAGR of -0.94% over 2 years The revenue of Cohance Lifesciences Ltd for the Dec '25 is ₹ 550.71 crore as compare to the Sep '25 revenue of ₹ 571.17 crore. This represent the decline of -3.58% The revenue of Sotac Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Cohance Lifesciences Ltd for the Dec '25 is ₹ 96.65 crore as compare to the Sep '25 ebitda of ₹ 136.55 crore. This represent the decline of -29.22% The ebitda of Sotac Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 29.02 crore over 7 quarters. This represents a CAGR of -42.04% The net profit of Sotac Pharmaceuticals Ltd changed from ₹ 1.35 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Sotac Pharmaceuticals Ltd changed from 13.94 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Cohance Lifesciences Ltd

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
May 7, 2025.
Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

About Sotac Pharmaceuticals Ltd

Sotac Pharmaceuticals Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name of 'M/s Sotac Pharmaceuticals', pursuant to a Deed of Partnership dated October 28, 2015.
Thereafter 'M/s.
Sotac Pharmaceuticals' was converted from Partnership Firm to a Private Limited Company in the name of 'Sotac Pharmaceuticals Private Limited' dated December 18, 2015 from the Assistant Registrar of Companies, Gujarat.
Later on, Company converted into a Public Limited Company and the name of Company was changed to 'Sotac Pharmaceuticals Limited' dated November 22, 2022 issued by Registrar of Companies, Ahmedabad. The Company is a part of SOTAC Group, based at Gujarat and is engaged in manufacturing of pharmaceutical products for different marketers on loan license or contract manufacturing basis.

FAQs for the comparison of Cohance Lifesciences Ltd and Sotac Pharmaceuticals Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Sotac Pharmaceuticals Ltd?

Market cap of Cohance Lifesciences Ltd is 18,399 Cr while Market cap of Sotac Pharmaceuticals Ltd is 117 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Sotac Pharmaceuticals Ltd?

The stock performance of Cohance Lifesciences Ltd and Sotac Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Sotac Pharmaceuticals Ltd?

As of May 7, 2026, the Cohance Lifesciences Ltd stock price is INR ₹480.95. On the other hand, Sotac Pharmaceuticals Ltd stock price is INR ₹106.0.

How do dividend payouts of Cohance Lifesciences Ltd and Sotac Pharmaceuticals Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Sotac Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.